Investment analysts at Oppenheimer initiated coverage on shares of Skye Bioscience (NASDAQ:SKYE - Get Free Report) in a research report issued on Friday, Marketbeat reports. The firm set an "outperform" rating and a $25.00 price target on the stock. Oppenheimer's price target indicates a potential upside of 93.65% from the stock's current price.
Separately, Piper Sandler reissued an "overweight" rating and issued a $20.00 price target (up previously from $12.00) on shares of Skye Bioscience in a research report on Thursday, March 14th.
Read Our Latest Research Report on Skye Bioscience
Skye Bioscience Price Performance
Shares of NASDAQ SKYE traded up $0.22 during midday trading on Friday, hitting $12.91. The company's stock had a trading volume of 51,800 shares, compared to its average volume of 26,472. Skye Bioscience has a one year low of $1.44 and a one year high of $19.41.
About Skye Bioscience
(
Get Free Report)
Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
See Also
Before you consider Skye Bioscience, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Skye Bioscience wasn't on the list.
While Skye Bioscience currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.
Get This Free Report
